Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD

PLoS ONE

Volumn 3, Issue 5, 2008, Pages

  Busso, Nathalie ^a   Karababa, Mahir ^a   Nobile, Massimo ^b   Rolaz, Aline ^b   Van Gool, Frédéric ^c   Galli, Mara ^c   Leo, Oberdan ^c   So, Alexander ^a   De Smedt, Thibaut ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b BioAlliance Pharma   (France)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; APO 866; COLLAGEN; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PHOSPHORIBOSYLTRANSFERASE; PLACEBO; RANTES; TUMOR NECROSIS FACTOR ALPHA; VISFATIN; ENZYME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CELL LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; ENDOTOXEMIA; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATORY CELL; INFLAMMATORY DISEASE; LEUKOCYTE FUNCTION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE METABOLISM; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; ANIMAL; BLOOD; C57BL MOUSE; DBA MOUSE; DRUG ANTAGONISM; ENZYMOLOGY; INFLAMMATION; METABOLISM; UPREGULATION;

MUS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; COLLAGEN; ENZYME INHIBITORS; FEMALE; HUMANS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 48249105497     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002267     Document Type: Article

References (45)

1. Andreakos ET, Foxwell BM, Brennan FM, Maini RN, Feldmann M (2002) Cytokines and and-cytokine biologicals in autoimmunity: present and future. Cytokine Growth Factor Rev 13: 299-313.
2. Jia SH, Li Y, Parodo J, Kapus A, Fan L, et al. (2001) Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest l13: 1318-1327.
3. Rongvaux A, Andris F, Van Gool F, Leo O (2003) Reconstructing eukaryotic NAD metabolism. Bioessays 25: 683-690.
4. Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, et al. (2002) Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 32: 3225-3234.
5. Samal B, Sun Y, Stearns G, Xie C, Suggs S, et al. (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14: 1431-1437.
6. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, et al. (2005) Visfatin: a protein secreted by visceral that mimics the effects of insulin. Science 307: 426-130.
7. Iqbal J. Zaidi M 2006 TNF regulates cellular NAD+ metabolism in primary macrophages. Biochem Biophys Res Commun 342: 1312-1318.
8. Nau GJ, Richmond JF, Schlesinger A, Jennings EG, Lander ES, et al. (2002) Human macrophage activation programs induced by bacterial pathogens, Proc Natl Acad Sci U S A 99: 1503-1508.
9. Huang Q, Liu D, Majewski P, Schulte LC, Kurn JM, et al. (2001) The plasticity of dendritic cell responses to pathogens and their components. Science 294: 870-875.
10. Ognjanovic S, Bao S, Yamamoto SY, Garibay-Tupas J, Samal B, et al. (2001) Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membrancs. J Mol Endocrinol 26: 107-117.
11. Ye SQ Simon BA, Maloney JP, Zamibelli-Weiner A, Gao L, et al. (2005) Pre-B-cell colony-enhancing factor as a potential novel biomarker in acute lung injury. Am J Respir Crit Care Med 171: 361-370.
12. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, et al. (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178: 1748-1758.
13. Otero M, Lago R, Gomez R, Lago F, Dieguez C, et al. (2006) Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 65: 1198-1201.
14. Nowell MA, Richards PJ, Fielding CA, Ognjanovic S, Topley N, et al. (2006) Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis, Arthritis Rheum 54: 2084-2095.
15. Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, et al. (2007) Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid. arthritis with proinflammattory and matrix-degrading activities. Arthritis Rheum 56: 2829-2839.
16. Khan JA, Tau X, Tong L (2006) Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol 13: 582-588.
17. Kim MK, Lee JH, Kim H, Park SJ, Kim SH, et al. (2006) Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyl-transferase, free and in complex with the anti-cancer agent FK-866. J Mol Biol 362: 66-77.
18. Wosikowski K, Mattern K, Schemainda I, Hasmann M, Rattel B, et al. (2002), WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells. Cancer Res 62: 1057-1062.
19. Hasmann M, Schemainda I (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res 63: 7436-7442.
20. Muruganandham M, Alfieri AA, Matei C, Chen Y, Sukenick G, et al. (2005) Metabolic signatures associated with a NAD synthesis inhibitor-induced tumor apoptosis identified by 1H-decoupled-31P magnetic resonance spectroscopy. Clin Cancer Res 11: 3503-3513.
21. Moller B, Villiger PM (2006) Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases. Springer Semin Immunopathol 27: 391-408.
22. Ziegler M (2000) New functions of a long-known molecule. Emerging roles of NAD in cellular signaling. Eur J Biochem 267: 1550-1564.
23. Guarente L (2006) Sirtuins as potential targets for metabolic syndrome. Nature 444: 868-874.
24. Michan S, Sinclair D (2007) Sirtuins in mammals: insights into their biological function. Biochem J 404: 1-13.
25. Hassa PO, Hottiger MO (2002) The functional role of poly(ADP-ribose)poly-merase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell Mol Life Sci 59: 1534-1553.
26. LeClaire RD, Kell W, Bavari S, Smith TJ, Hunt RE (1996) Protective effects of niacinamide in staphylococcal enterotoxin-B-induced toxicity. Toxicology 107: 69-81.
27. Pero RW, Axelsson B, Siemann D, Chaplin D, Dougherty G 1991 Newly discovered anti-inflammatory properties of the benzamides and nicotinamides. Mol Cell Biochcm 193: 119-125.
28. Revollo JR, Grimm AA, Imai S (2001) The NAD biosynhesis pathway mediated by niconamide phosphoribosyltransferase regulates Sir-2 activity in mammalian cells. J Biol Chem 279: 50751-50763.
29. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, et al. (2007) Retraction. Science 318: 565.
30. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, et al. (2007) Nampt/ PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 6: 363-375.
31. Mohammed FF, Smookler DS, Khokha R (2003) Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rheum Dis 62Suppl 2: ii43-47.
32. Tanaka M, Nozaki M, Fukuhara A, Segawa K, Aoki N, et al. (2007) Visfatin is released from 3T3-Ll adipocytes via a non-classical pathway. Biochem Biophys Res Commun 359: 194-201.
33. Revollo JR, Grimm AA, Imai S (2007) The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol 23: 164-170.
34. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, et al. (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 11: 1-15.
35. Swierkot J, Szechinski J (2006) Methotrexate in rheumatoid arthritis. Pharmacol Rep 58: 473-492.
36. Pogrebniak A, Schemainda I, Azza K, Pelka-Fleischer R, Nussler V, et al. (2006) Chemopotentiating effects of a novel NAD biosynthesis inhibitor, FK866, in combination with antineoplastic agents. Eur J Med Res 11: 313-321.
37. Bae SK, Kim SR, Kim JG, Kim JY, Koo TH, et al. (2006) Hypoxic induction of human visfatin genr is directly mediated by hypoxia-inducible factor-1. FEBS Lett 580: 4105-4113.
38. Segawa K, Fukuhara A, Hosogai N, Morita K, Okuno Y, et al. (2006) Visfatin in adipocytes is upregulated by hypoxia through HIFlalpha-dependent mechanism. Biochem Biophys Res Commun 349: 875-882.
39. Kim SR, Bae SK, Choi KS, Park SY, Jun HO, et al. (2007) Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun 357: 150-156.
40. Taylor PC, Sivakumar B (2005) Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol 17: 293-298.
41. Lee YA, Kim JY, Hong SJ, Lee SH, Yoo MG, et al. (2007) Synovial proliferation differentially affects hypoxia in the joint cavities of rheumatoid arthritis and osteoarthritis patients. Clin Rheumatol.
42. Veale DJ, Fearon U (2006) Inhibition of angiogenic pathways in rheumatoid arthritis potential for therapeutic targeting. Best Pract Res Clin Rheumatol 20: 941-947.
43. Peacock DJ, Banquerigo ML, Brahn E. (1992) Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 175: 1135-1138.
44. Drevs J, Loser R, Rattel B, Esser N (2003) Antiangiogenic potency of FK866/K22.175, a new inhibitor of intracellular NAD biosynthesis, in murine renal cell carcinoma. Anticancer Res 23: 4853-4858.
45. Wagner TC, Scott MD (1994) Single Extraction Method for the Spectropho-tometric Quantification of Oxidized and Reduced Pyridine Nucleotides in Erythrocytes: Analytical Biochemistry 222: 117-126.